NeoGenomics Provides 2026 Revenue Outlook Following PanTracer Liquid MolDX Approval

NeoGenomics (NASDAQ:NEO) announced a 2026 revenue outlook of $797 million to $803 million following the approval of its PanTracer Liquid MolDX product. The company reported Q1 2026 revenue of $186.7 million, up 11% year-over-year, along with adjusted EBITDA of $9 million and clinical revenue of $171 million.

By SA Transcript Insights Editor, SA News Editor · Seeking Alpha · April 29, 2026, 07:52 UTC

Tickers: $NEO

Topics: Clinical Revenue Earnings Report EBITDA Management Commentary Revenue Growth

Read the full article at Seeking Alpha

More World news

Jensen Huang Resigns as Nvidia CEO Amid Personal Conduct Controversies and China Export Investigations Motley Fool · November 12, 2026, 18:56 UTC
The Adecco Group Reports Q3 2026 Growth Driven by Temporary Staffing and Margin Expansion PR Newswire · November 12, 2026, 18:54 UTC
Twist Bioscience Projects FY2027 Revenue Between $550M and $560M Seeking Alpha · November 12, 2026, 18:50 UTC
Dixie Group Reports Q3 Sales Growth Amid Margin Pressure and Future Cost-Reduction Targets Seeking Alpha · November 12, 2026, 18:50 UTC
Data I/O Corporation Targets Rapid V-TEK Synergy Realization Amid $80 Million M&A Pipeline Seeking Alpha · November 12, 2026, 18:50 UTC
Leatt Corporation Reports 43% Increase in Q3 Revenue to $20.46 Million Seeking Alpha · November 12, 2026, 18:50 UTC
Parsons Reports Strong Third Quarter Results Driven by High-Margin Product Shift Motley Fool · November 12, 2026, 18:45 UTC
C.H. Robinson Reports Q3 2026 Earnings Driven by AI Efficiency and Margin Expansion Motley Fool · November 12, 2026, 18:45 UTC
Baker Hughes Raises Guidance Amid Surging Data Center Power Demand Motley Fool · November 12, 2026, 18:45 UTC
California Supreme Court to Rule on Insurance Overcharge Liability Under Proposition 103 PR Newswire · November 12, 2026, 18:44 UTC